Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 1 |
2004 | 1 |
2005 | 1 |
2006 | 1 |
2009 | 1 |
2013 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
Leukemia. 2022 Mar;36(3):701-711. doi: 10.1038/s41375-021-01462-4. Epub 2021 Nov 8.
Leukemia. 2022.
PMID: 34750506
Free PMC article.
Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Bauer RC, Sänger J, Peschel C, Duyster J, von Bubnoff N.
Bauer RC, et al. Among authors: sanger j.
Clin Cancer Res. 2013 Jun 1;19(11):2962-72. doi: 10.1158/1078-0432.CCR-13-0052. Epub 2013 Apr 2.
Clin Cancer Res. 2013.
PMID: 23549879
Item in Clipboard
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J.
von Bubnoff N, et al. Among authors: sanger j.
Cancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24.
Cancer Res. 2009.
PMID: 19318574
Item in Clipboard
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.
von Bubnoff N, et al. Among authors: sanger j.
Blood. 2005 Feb 15;105(4):1652-9. doi: 10.1182/blood-2004-06-2445. Epub 2004 Sep 30.
Blood. 2005.
PMID: 15459011
Free article.
Item in Clipboard
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J.
von Bubnoff N, et al. Among authors: sanger j.
Blood. 2006 Aug 15;108(4):1328-33. doi: 10.1182/blood-2005-12-010132. Epub 2006 Apr 13.
Blood. 2006.
PMID: 16614241
Free article.
Item in Clipboard
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J.
von Bubnoff N, et al. Among authors: sanger j.
Cancer Res. 2003 Oct 1;63(19):6395-404.
Cancer Res. 2003.
PMID: 14559829
Item in Clipboard
Cite
Cite